Patents by Inventor Tusharmouli Mukherjee
Tusharmouli Mukherjee has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230084536Abstract: The present invention relates to a pharmaceutical cold kit composition comprising a chelating agent linked to somatostatin receptor binding organic moiety, a stabilizer, a buffer, and a caking agent or bulking agent, wherein the composition is free of sequestering agent. Further, the present invention also relates to the process of preparing reconstituted or radiolabeled solution composition having high in use stability and radiochemical purity and use thereof for diagnostic and/or therapeutic purposes.Type: ApplicationFiled: September 12, 2022Publication date: March 16, 2023Applicant: Jubilant RadiopharmaInventors: Vijayaraj Kuniyil Kulangara, Riadh Zriba, Tusharmouli Mukherjee, Indranil Nandi, Miriam Ruiz Pena
-
Patent number: 11583521Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: GrantFiled: June 30, 2021Date of Patent: February 21, 2023Assignee: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee
-
Publication number: 20230012402Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using the prepared dosage forms for the removal of undesirable body fat for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical and clinical attributes.Type: ApplicationFiled: September 8, 2022Publication date: January 12, 2023Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Nagabasayya R. Chikkamath, Dinesh Kumar, Tusharmouli Mukherjee
-
Publication number: 20230000837Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: ApplicationFiled: April 20, 2022Publication date: January 5, 2023Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R. Chikkamath
-
Publication number: 20220265552Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology. The suspension compositions as per present invention are useful for the treatment of seizures, partial-onset seizures, epilepsy, neuropathic pain, migraine, fibromyalgia, trigeminal neuralgia, bipolar disorders, attention disorders, anxiety disorders, affective disorders, schizoaffective disorders, sensorimotor disorders, and vestibular disorders.Type: ApplicationFiled: May 2, 2022Publication date: August 25, 2022Applicant: Jubilant Generics LimitedInventors: Indranil Nandi, Dinesh Kumar, Rakesh Singh, TUSHARMOULI MUKHERJEE
-
Publication number: 20220202698Abstract: Provided herein are the extended release pharmaceutical composition suitable for once or twice daily dosing comprising riociguat and at least one or more pharmaceutically acceptable excipients. The present invention also relates to method for preparing extended release composition and method of using these dosage forms for the treatment of pulmonary hypertension and related diseases. The present invention provides extended release composition of riociguat which are expected to exhibit desired technical attributes such as assay, stability and release profile suitable for once or twice daily administration.Type: ApplicationFiled: December 27, 2021Publication date: June 30, 2022Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh Kumar Singh
-
Patent number: 11318145Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.Type: GrantFiled: May 21, 2021Date of Patent: May 3, 2022Inventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
-
Patent number: 11311518Abstract: Disclosed are the injection compositions of ?3 adrenoreceptor agonists such as mirabegron or their pharmaceutically acceptable salts or solvates or esters thereof. The present invention also relates to methods for preparing injection compositions and methods of using these dosage forms for the treatment of obesity, other related metabolic diseases, and reduction/removal of fat. The injection compositions as per the present invention have advantages of simple preparation, simple and convenient application, easy absorption, and better effect of treating. The compositions can also be used in cases where oral administration of the drug is not possible due to underlying conditions or concerns around inadequate oral absorption. The injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: GrantFiled: August 6, 2021Date of Patent: April 26, 2022Assignee: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee, Nagabasayya R Chikkamath
-
Publication number: 20220000843Abstract: Provided herein are the long-acting injection compositions of ?3 adrenoreceptor agonists like mirabegron or their pharmaceutically acceptable salts or esters thereof. The present invention also relates to methods for preparing long-acting injection compositions and methods of using these dosage forms for the treatment of obesity, metabolic diseases, and other diseases as described herein. The long-acting injection compositions as per the present invention have desirable pharmaceutical technical attributes.Type: ApplicationFiled: June 30, 2021Publication date: January 6, 2022Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee
-
Publication number: 20210369619Abstract: The present invention relates to the transmucosal dosage forms like sublingual pharmaceutical compositions comprising antiviral molecules like favipiravir, remdesivir, baloxavir marboxil, molnupiravir, besifovir, raltegravir, GS-441524, ravidasvir, and other antiviral drugs. The present invention also relates to methods for preparing these transmucosal pharmaceutical compositions. Compositions prepared as per the present invention are able to increase bioavailability by avoiding first-pass metabolism. The compositions prepared as per the present invention exhibit desired pharmaceutical technical attributes such as pH, assay, related substance, disintegration, and dissolution. The compositions prepared as per the present invention are useful in the treatment of viral infections including coronavirus infection (COVID-19).Type: ApplicationFiled: May 25, 2021Publication date: December 2, 2021Applicant: Jubilant Generics LimitedInventors: Indranil Nandi, Tusharmouli Mukherjee, Dinesh Kumar, Anil Jain, Pankaj Soni, Gaurav Navinbhai Mistry, Nilesh Jaiswal
-
Publication number: 20210353546Abstract: The present invention relates to a pharmaceutical composition comprising a combination of mirabegron and solifenacin or their pharmaceutically acceptable salts, wherein the composition comprises mini-tablets, multiparticulates, inlay tablets, or bilayer tablets. The prior art discloses restrictive formulation techniques and suggests complexity for preparing the combination in a single formulation to achieve the desired technical attributes. The test formulations are stable and exhibit desired pharmaceutical technical attributes. The invention also relates to the use of the pharmaceutical composition of the present invention in the treatment of various diseases like overactive bladder and other related therapeutic indications.Type: ApplicationFiled: May 11, 2021Publication date: November 18, 2021Applicant: Jubilant Pharma Holdings Inc.Inventors: Indranil Nandi, Tusharmouli Mukherjee
-
Publication number: 20210275539Abstract: The present invention relates to oral ready to use liquid pharmaceutical compositions of eslicarbazepine. It also relates to the processes for the preparation of said liquid compositions. The present invention provides liquid compositions of eslicarbazepine with desired technical attributes such as release profile, viscosity, pH, stability, and acceptable organoleptic properties. The prepared compositions are useful in patients having difficulties in swallowing tablets and provide the physician with providing a more convenient and less cumbersome posology.Type: ApplicationFiled: May 21, 2021Publication date: September 9, 2021Applicant: Jubilant Generics LimitedInventors: Indranil Nandi, TUSHARMOULI MUKHERJEE, Dinesh Kumar, Rakesh K. Singh, Saurabh Srivastava
-
Patent number: 9114171Abstract: A liquid composition comprising racecadotril and cyclodextrin.Type: GrantFiled: December 23, 2013Date of Patent: August 25, 2015Assignee: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Tusharmouli Mukherjee
-
Patent number: 9084721Abstract: A liquid composition comprising racecadotril and cyclodextrin.Type: GrantFiled: June 28, 2013Date of Patent: July 21, 2015Assignee: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Tusharmouli Mukherjee
-
Publication number: 20140274948Abstract: A liquid composition comprising racecadotril and cyclodextrin.Type: ApplicationFiled: December 23, 2013Publication date: September 18, 2014Applicant: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Tusharmouli Mukherjee
-
Publication number: 20140005261Abstract: A liquid composition comprising racecadotril and cyclodextrin.Type: ApplicationFiled: June 28, 2013Publication date: January 2, 2014Applicant: McNeil-PPC, Inc.Inventors: Der-Yang Lee, Tusharmouli Mukherjee